Biomedical Occupation or Discipline

VantAI and Halda Strike $1B+ AI-Driven Partnership on ‘Hold-and-Kill’ Drugs

4 days ago talkbio0Tagged Aortic Valve Insufficiency, cellular targeting, Chimera organism, Drug Discovery, Halda Therapeutics, hold-and-kill, Immunology, Induce (action), Neoplasms, Proximity, RIPTAC, target-effector pairs, VantAI

VantAI; Halda Therapeutics; RIPTAC drugs; hold-and-kill; AI drug discovery; target-effector pairs; oncology; immunology; regulated induced proximity targeting chimeras; $1 billion deal

Shankar Ramaswamy’s Kriya Therapeutics Raises $313M for Gene Therapy Advancements

4 days ago talkbio0Tagged Biotechnology, gene therapy, Kriya, Shankar Ramaswamy, venture

Kriya Therapeutics; Shankar Ramaswamy; gene therapy; biotech funding; fundraising; biotechnology; venture capital; 2025

Merck KGaA and Skyhawk Therapeutics Launch $2B RNA-Targeting Neurology Collaboration

4 days ago talkbio0Tagged Billion Collaboration, Drug Development, Merck KGaA, milestone payments, nervous system disorder, RNA-targeting, royalties, Skyhawk, SkySTAR platform

Merck KGaA; Skyhawk Therapeutics; RNA-targeting; SkySTAR platform; neurological disorders; $2 billion collaboration; drug development; milestone payments; royalties

Reunion Psychedelic Therapy Advances to Pivotal Trials after Postpartum Depression Success

4 days ago talkbio0Tagged Clinical Trials, Depression, Postpartum, Montgomery-Åsberg Depression Rating Scale, Montgomery-Asberg Depression Rating Scale Questionnaire, Neuroscience discipline, Phase 2 Clinical Trials, Phase 3 Clinical Trials, psychedelic therapy, RE104, RECONNECT, remission rates, Reunion

Reunion Neuroscience; RE104; psychedelic therapy; postpartum depression (PPD); Phase II trial; Phase III trial; RECONNECT trial; clinical trial results; Montgomery-Åsberg Depression Rating Scale (MADRS); remission rates

XtalPi and DoveTree Announce Landmark $6 Billion AI-Powered Drug Discovery Collaboration

2 weeks ago talkbio0Tagged Aortic Valve Insufficiency, Artificial Intelligence, Collaboration, Dosage Forms, DoveTree Medicines, Drug Discovery, Gregory Verdine, Immunology, Metabolic Diseases, milestone payments, Neoplasms, Neurology speciality, Robotics, royalties, upfront payment, XtalPi

XtalPi; DoveTree Medicines; AI drug discovery; robotics; pharmaceutical R&D; Gregory Verdine; oncology; immunology; neurology; metabolic diseases; collaboration; upfront payment; milestone payments; royalties

AstraZeneca Expands AI Collaboration with SOPHiA GENETICS for Breast Cancer Research

2 weeks ago talkbio0Tagged AI Factories, AstraZeneca, Clinical Data, Genomics, Malignant neoplasm of breast, predictive models, real-world evidence, SOPHiA GENETICS

AstraZeneca; SOPHiA GENETICS; AI Factories; breast cancer; predictive models; real-world evidence; genomics; clinical data

Pfizer’s Embattled Obesity Program Loses Another GLP-1 Drug Due to Data and Competition Issues

3 weeks ago talkbio0Tagged Agonist, Clinical Trials, competition, Danuglipron, Drug Development, Glucagon-Like Peptide 1, Injury of liver, lotiglipron, Obesity, PF-06954522, Pfizer

Pfizer; obesity; GLP-1 agonist; clinical trial; liver injury; danuglipron; lotiglipron; PF-06954522; obesity drug development; competition

BioMarin Drops Preclinical PKU Drug Once Seen as Potential Palynziq Successor

3 weeks ago talkbio0Tagged BioMarin, Drug Development, Immunogenicity (package insert), Palynziq, Phenylketonurias, R&D pipeline

BioMarin; PKU; Palynziq; BMN 390; drug development; R&D pipeline; immunogenicity

Vertex Drops Next-Generation Pain Drug After Phase 2 Failure, Casts Doubt on Broader Journavx Expansion

3 weeks ago talkbio0Tagged Acute onset pain, Approved, Drug Development, Journavx, non-opioid pain drugs, Pain management, Peripheral neuropathic pain, Sodium Channel Blockers, United States Food and Drug Administration, VX-993

Vertex Pharmaceuticals; Journavx; VX-993; pain management; acute pain; phase 2 clinical trial; sodium channel inhibitor; non-opioid pain drugs; FDA approval; peripheral neuropathic pain; drug development

AbbVie Raises 2025 Guidance and Eyes Strategic Deals in Neuroscience, Obesity, and Oncology

3 weeks ago talkbio0Tagged AbbVie, Advice, earnings, Neuroscience discipline, Obesity, PD-1/VEGF, Strategic Deals

AbbVie; 2025 guidance; earnings; neuroscience; obesity; PD-1/VEGF; strategic deals; pharmaceuticals